General Information of Drug (ID: DMDYA31)

Drug Name
Pretomanid
Synonyms
PA-824; 187235-37-6; Pretomanid; PA 824; PA824; UNII-2XOI31YC4N; (S)-PA 824; (S)-2-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; 2XOI31YC4N; CHEMBL227875; MMV688755; AK161427; (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-6,7-Dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine; Pretomanid [USAN:INN]; C14H12F3N3O5; PA-824(Pretomanid); AC1L9UFX; Pretomanid (USAN/INN); MLS006011141; SCHEMBL2983011
Indication
Disease Entry ICD 11 Status REF
Tuberculosis 1B10-1B14 Approved [1]
Mycobacterium infection 1B10-1B21 Phase 3 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 359.26
Logarithm of the Partition Coefficient (xlogp) 2.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 28.1 mgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 1.7 mg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4-5 h [3]
Clearance
The clearance of drug is 4.8 +/- 0.2 L/h [4]
Elimination
An average of about 53% of the radioactive dose was found to be excreted in the urine [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 16.9 - 17.4 hours [3]
Vd
The volume of distribution (Vd) of drug is 130 +/- 5 L [4]
Chemical Identifiers
Formula
C14H12F3N3O5
IUPAC Name
(6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
Canonical SMILES
C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F
InChI
InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1
InChIKey
ZLHZLMOSPGACSZ-NSHDSACASA-N
Cross-matching ID
PubChem CID
456199
CAS Number
187235-37-6
DrugBank ID
DB05154
TTD ID
D02AYL
INTEDE ID
DR1338
ACDINA ID
D01360
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mycobacterium Mycolic acid synthase (MycB cma) TT08ESN CMAS1_MYCTU ; CMAS2_MYCTU ; CMAS3_MYCTU Inhibitor [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME
DE4LYSA CP3A4_HUMAN Substrate [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Pretomanid (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Major Increased metabolism of Pretomanid caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [6]
Pexidartinib DMS2J0Z Major Increased metabolism of Pretomanid caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [6]
Lumacaftor DMCLWDJ Major Increased metabolism of Pretomanid caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [7]
Cenobamate DM8KLU9 Major Increased metabolism of Pretomanid caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [6]
Eslicarbazepine DMZREFQ Major Increased metabolism of Pretomanid caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [6]
Etravirine DMGV8QU Major Increased metabolism of Pretomanid caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [6]
PF-06463922 DMKM7EW Major Increased metabolism of Pretomanid caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [6]
Dabrafenib DMX6OE3 Major Increased metabolism of Pretomanid caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [6]
Abametapir DM2RX0I Moderate Decreased metabolism of Pretomanid caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [8]
Lefamulin DME6G97 Moderate Decreased metabolism of Pretomanid caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [9]
Enzalutamide DMGL19D Major Increased metabolism of Pretomanid caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [6]
Telotristat ethyl DMDIYFZ Major Increased metabolism of Pretomanid caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [7]
Pitolisant DM8RFNJ Major Increased metabolism of Pretomanid caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [6]
⏷ Show the Full List of 13 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Pretomanid 200 mg tablet 200 mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 ClinicalTrials.gov (NCT02342886) Shortening Treatment by Advancing Novel Drugs. U.S. National Institutes of Health.
3 Pretomanid FDA label, August 2019
4 Lyons MA: Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients. Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: AAC.02359-17. doi: 10.1128/AAC.02359-17. Print 2018 Jul.
5 FDA briefing document - pretomanid tablet, 200 mg meeting of the antimicrobial drugs advisory committee (AMDAC).
6 Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
7 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
8 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
9 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.